• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Geron Corporation

    5/27/26 4:01:30 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GERN alert in real time by email
    8-K
    GERON CORP CA false 0000886744 0000886744 2026-05-20 2026-05-20
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): May 20, 2026

     

     

    GERON CORPORATION

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   000-20859   75-2287752

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    919 E. HILLSDALE BLVD., SUITE 250
    FOSTER CITY, CALIFORNIA 94404
    (Address of principal executive offices, including zip code)

    (650) 473-7700

    (Registrant’s telephone number, including area code)

    N/A

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $0.001 par value   GERN   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    (e)

    Amendment to 2018 Equity Incentive Plan

    As further described below, at the 2026 Annual Meeting of Stockholders of Geron Corporation (the “Company”) held on May 20, 2026 (the “2026 Annual Meeting”), the Company’s stockholders approved an amendment and restatement of the Company’s 2018 Equity Incentive Plan to, among other items, increase the number of shares of the Company’s common stock issuable thereunder by 4,500,000 shares (as so amended and restated, the “Amended 2018 Plan”), which had previously been adopted by the Company’s board of directors (the “Board”), subject to stockholder approval. A description of the terms and conditions of the Amended 2018 Plan is set forth on pages 35 to 49 in the Company’s definitive proxy statement for the 2026 Annual Meeting filed with the Securities and Exchange Commission (the “SEC”) on April 7, 2026 (the “2026 Proxy Statement”) and is incorporated herein by reference. Such description does not purport to be complete and is qualified in its entirety by the full text of the Amended 2018 Plan, which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

    Item 5.07 Submission of Matters to a Vote of Security Holders.

    The Company’s 2026 Annual Meeting was held on May 20, 2026 in a virtual meeting format, pursuant to notice duly given. Only stockholders of record as of the close of business on March 26, 2026, the record date for the 2026 Annual Meeting, were entitled to vote at the 2026 Annual Meeting. The final results of the stockholder vote on each proposal brought before the 2026 Annual Meeting are as follows:

     

    1.

    Proposal 1. The Company’s stockholders elected each of the three (3) nominees to hold office as Class III directors to serve for a three-year term expiring at the Company’s 2029 annual meeting of stockholders and until her successor is duly elected and qualified or until her earlier resignation or removal. The election of such Class III directors was based upon the following votes:

     

    Name of Director Nominee

       Votes For      Votes Withheld      Broker Non-Votes  

    Susan M. Molineaux

         355,206,267        37,996,712        104,595,534  

    Patricia S. Andrews

         387,194,039        6,008,940        104,595,534  

    Constantine Chinoporos

         387,061,554        6,141,425        104,595,534  

     

    2.

    Proposal 2. The Company’s stockholders approved the amendment to the Company’s 2018 Equity Incentive Plan to, among other items, increase the number of shares of the Company’s common stock issuable thereunder by 4,500,000 shares, based upon the following votes:

     

    Votes For

     

    Votes Against

     

    Votes Abstaining

     

    Broker Non-Votes

    370,294,696   21,853,005   1,055,278   104,595,534

     

    3.

    Proposal 3. The Company’s stockholders approved the non-binding, advisory vote to approve the compensation paid to the Company’s named executive officers as disclosed in the 2026 Proxy Statement, based upon the following votes:

     

    Votes For

     

    Votes Against

     

    Votes Abstaining

     

    Broker Non-Votes

    372,129,132   19,673,460   1,400,387   104,595,534

     

    4.

    Proposal 4. The Company’s stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, based upon the following votes:

     

    Votes For

     

    Votes Against

     

    Votes Abstaining

     

    Broker Non-Votes

    486,459,028   9,474,870   1,864,615   N/A

     


    Item 9.01 Financial Statements and Exhibits.

    (4) Exhibits.

     

    Exhibit No.    Description
    10.1    Geron Corporation 2018 Equity Incentive Plan, as amended
    104    Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

     


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

          GERON CORPORATION
    Date: May 27, 2026     By:  

    /s/ Timothy Williams

        Name:   Timothy Williams
        Title:   Executive Vice President,
         

    Chief Legal Officer and Corporate

    Secretary

    5

    Get the next $GERN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GERN

    DatePrice TargetRatingAnalyst
    7/10/2025$1.00Sell
    Goldman
    5/8/2025$1.50Sector Outperform → Sector Perform
    Scotiabank
    2/27/2025$3.50 → $2.00Buy → Neutral
    B. Riley Securities
    2/26/2025Buy → Neutral
    H.C. Wainwright
    11/5/2024$8.00Buy
    H.C. Wainwright
    10/16/2024Sector Outperform
    Scotiabank
    9/9/2024$7.00Outperform
    Leerink Partners
    4/30/2024$4.50Outperform → Neutral
    Robert W. Baird
    More analyst ratings

    $GERN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lawlis V Bryan bought $15,667 worth of shares (13,300 units at $1.18) (SEC Form 4)

    4 - GERON CORP (0000886744) (Issuer)

    5/13/25 4:20:43 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Legal Officer Samuels Scott Alan bought $24,150 worth of shares (15,000 units at $1.61), increasing direct ownership by 128% to 26,682 units (SEC Form 4)

    4 - GERON CORP (0000886744) (Issuer)

    3/3/25 6:01:08 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, President and CEO Scarlett John A bought $22,062 worth of shares (12,500 units at $1.76) (SEC Form 4)

    4 - GERON CORP (0000886744) (Issuer)

    3/3/25 6:01:06 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    SEC Filings

    View All

    SEC Form 8-K filed by Geron Corporation

    8-K - GERON CORP (0000886744) (Filer)

    5/27/26 4:01:30 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Geron Corporation

    SCHEDULE 13G/A - GERON CORP (0000886744) (Subject)

    5/8/26 5:01:11 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Geron Corporation

    10-Q - GERON CORP (0000886744) (Filer)

    5/6/26 4:49:33 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

    FOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m. ET in Miami, FL. A live and archived audio webcast of the fireside chat will be available through the Investors & Media section of Geron's website at www.geron.com. About GeronGeron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our firs

    6/1/26 8:00:00 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

    Cell therapies and precision biologics are driving new opportunities across longevity, cognitive health, and neurological disease sectorsNEW YORK, May 20, 2026 /PRNewswire/ -- Market News Updates News Commentary - Cell-based therapies are quickly becoming one of the most talked-about areas in healthcare as researchers move beyond traditional drugs and focus on repairing and regenerating the body at the cellular level. Instead of only treating symptoms, scientists are now exploring ways to potentially reverse damage tied to aging and chronic disease. In the anti-aging space, stem cells, regenerative biologics, and senolytic therapies are being studied for their potential to restore tissue fun

    5/20/26 9:50:00 AM ET
    $BIOA
    $FATE
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    FOSTER CITY, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that, effective May 15, 2026, it granted stock options to purchase an aggregate of 333,750 shares of common stock to five newly hired employees as an inducement material to such employees' acceptance of employment with Geron. The stock options have an exercise price of $1.29 per share, which is equal to the closing price of Geron's common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of such employee and

    5/18/26 4:01:00 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Spiegel Robert J.

    4 - GERON CORP (0000886744) (Issuer)

    5/26/26 7:45:16 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Molineaux Susan

    4 - GERON CORP (0000886744) (Issuer)

    5/26/26 7:45:09 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Mcdonald John F

    4 - GERON CORP (0000886744) (Issuer)

    5/26/26 7:45:07 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman resumed coverage on Geron with a new price target

    Goldman resumed coverage of Geron with a rating of Sell and set a new price target of $1.00

    7/10/25 8:55:29 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Geron downgraded by Scotiabank with a new price target

    Scotiabank downgraded Geron from Sector Outperform to Sector Perform and set a new price target of $1.50

    5/8/25 8:26:41 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Geron downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded Geron from Buy to Neutral and set a new price target of $2.00 from $3.50 previously

    2/27/25 6:20:37 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 7, 2024 - FDA Roundup: June 7, 2024

    For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

    6/7/24 3:46:22 PM ET
    $GERN
    $SRAX
    $SNAP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Advertising
    Consumer Discretionary

    FDA Approval for RYTELO issued to GERON CORP

    Submission status for GERON CORP's drug RYTELO (ORIG-1) with active ingredient IMETELSTAT has changed to 'Approval' on 06/06/2024. Application Category: NDA, Application Number: 217779, Application Classification: Type 1 - New Molecular Entity

    6/7/24 12:36:59 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    Financials

    Live finance-specific insights

    View All

    Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights

    Achieved $51.8 million in RYTELO® (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025 Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Strengthened leadership team with appointments of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary and Patricia S. Andrews and Constantine Chinoporos to Board of Directors Ended Q1 2026 with cash, cash equivalents, restricted cash and marketable securities of $341 million Company to host conference call and webcast today, May 6, 2026, at

    5/6/26 7:00:00 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Geron Plans to Present at Upcoming Investor Conferences

    FOSTER CITY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to present at the following investor conferences: Bank of America Securities 2026 Healthcare ConferencePresentation on Tuesday, May 12 at 4:35 p.m. ET in Las Vegas, NV 2026 Stifel Virtual Targeted Oncology ForumVirtual presentation on Wednesday, May 20 at 12:00 p.m. ET A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company's website at www.geron.com. About Ge

    5/5/26 8:00:00 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026

    FOSTER CITY, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its first quarter 2026 financial results and business highlights before the market opens on Wednesday, May 6, 2026 via press release, which will be available on the Investors and Media section of the Company's website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time. A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company's website at www.geron.com. About GeronGero

    4/22/26 7:00:00 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Geron Corporation

    SC 13G/A - GERON CORP (0000886744) (Subject)

    11/14/24 5:46:12 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Geron Corporation

    SC 13G/A - GERON CORP (0000886744) (Subject)

    11/14/24 9:31:41 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Geron Corporation

    SC 13G - GERON CORP (0000886744) (Subject)

    11/14/24 6:25:29 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    Leadership Updates

    Live Leadership Updates

    View All

    Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary

    FOSTER CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary. "Tim has deep expertise in the biopharmaceutical industry and a proven track record of leading the legal function at commercial-stage organizations," said Harout Semerjian, President and Chief Executive Officer of Geron. "The addition of Tim, coupled with our recent Board appointments, further strengthens our leadership team. His strategic counsel will be invaluable as we

    4/13/26 8:00:00 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Geron Announces Appointment of New Members to its Board of Directors

    FOSTER CITY, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Patricia S. Andrews and Constantine Chinoporos to its Board of Directors. "We are pleased to welcome Constantine and Pat to the Board, as they bring deep operational expertise cultivated over decades of biopharmaceutical industry leadership, particularly with commercial-stage organizations," said Elizabeth O'Farrell, Chair of the Board. "Their invaluable insights will be instrumental as we execute on our strategic priorities and drive commercial growth for RYTE

    3/26/26 8:00:00 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)